Skip to main content
. Author manuscript; available in PMC: 2017 Nov 13.
Published in final edited form as: Vaccine. 2016 Sep 13;34(44):5366–5375. doi: 10.1016/j.vaccine.2016.08.063

Table 1.

WNVΔCtrl virus neuroinvasiveness and neurovirulence in mice.

Dose (IU) WT WNV Survivors/Total[AST (days) of decedents]
WNVΔCtrl-1 Survivors/Total [AST (days) of decedents]
WNVΔCtrl-2a Survivors/Total [AST (days) of decedents]
WNVΔCtrl-2b Survivors/Total [AST (days) of decedents]
WNVΔCtrl-3 Survivors/Total [AST (days) of decedents]
Route IC IP IC IP IC IP IC IP IC IP
10−1 2/5 (7.3) ND 3/5 (7) ND 5/5 ND 5/5 ND 5/5 ND
100 1/5 (7.5) 3/5 (7) 1/5 (7.8) 5/5 3/5 (10) 5/5 5/5 5/5 5/5 5/5
101 0/5 (6.6) 2/5 (7) 1/5 (7) 3/5 (8) 5/5 4/5 (9) 3/5 (10.5) 4/5 (8) 4/5 (8) 4/5 (9)
102 ND 1/5 (7) 0/5 (6.4) 3/5 (7) 1/5 (8.5) 4/5 (9) 0/5 (7.8) 2/5 (8) 1/6 (6.8) 2/5 (9)
103 ND ND ND 0/5 (6.4) ND 2/5 (8) ND 2/5 (10.7) ND 2/5 (8)
LD50 as log10 (IU) (95% CI) −1.18 (−2.43,0.08) 0.48 (−0.90,1.87) −0.75 (−1.90,0.40) 1.71 (1.04,2.39) 1.49 (0.44,2.54) 2.75 (1.60,3.90) 1.02 (−9.30,11.34) 2.23 (1.27,3.18) 1.48 (0.99,1.97) 2.23 (1.27,3.18)